Last reviewed · How we verify

Drug: LY573636-sodium

Eli Lilly and Company · Phase 1 active Small molecule

Drug: LY573636-sodium is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development. Also known as: Tasisulam.

At a glance

Generic nameDrug: LY573636-sodium
Also known asTasisulam
SponsorEli Lilly and Company
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Drug: LY573636-sodium

What is Drug: LY573636-sodium?

Drug: LY573636-sodium is a Small molecule drug developed by Eli Lilly and Company.

Who makes Drug: LY573636-sodium?

Drug: LY573636-sodium is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is Drug: LY573636-sodium also known as anything else?

Drug: LY573636-sodium is also known as Tasisulam.

What development phase is Drug: LY573636-sodium in?

Drug: LY573636-sodium is in Phase 1.

Related